Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Watanabe Oyster Laboratory Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners but share 1 art unit, indicating separate examiner relationships within a common technical setting.
ROCHELLE, CIERRA MARIE is the busiest examiner, with 1 pending matter. Counsel can coordinate technical treatment across the shared art unit while tailoring responses to each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18870594 | 8-OHdG CONCENTRATION DECREASE ACCELERATOR, MALONDIALDEHYDE (MDA) CONCENTRATION DECREASE ACCELERATOR, ZIP4 CONCENTRATION INCREASE ACCELERATOR, OR SERUM ZINC CONCENTRATION INCREASE ACCELERATOR FOR JEJUNUM | ROCHELLE, CIERRA MARIE | — |
| 18713980 | GROWTH INHIBITOR OF METASTATIC HUMAN PROSTATE CANCER CELLS | IVANOVA, SVETLANA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713980 | GROWTH INHIBITOR OF METASTATIC HUMAN PROSTATE CANCER CELLS | IVANOVA, SVETLANA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18870594 | 8-OHdG CONCENTRATION DECREASE ACCELERATOR, MALONDIALDEHYDE (MDA) CONCENTRATION DECREASE ACCELERATOR, ZIP4 CONCENTRATION INCREASE ACCELERATOR, OR SERUM ZINC CONCENTRATION INCREASE ACCELERATOR FOR JEJUNUM | ROCHELLE, CIERRA MARIE | 1627 | §103§112 | Non-Final OA | — | Pending | Nov 29, 2024 |
| 18713980 | GROWTH INHIBITOR OF METASTATIC HUMAN PROSTATE CANCER CELLS | IVANOVA, SVETLANA M | 1627 | §102§103 | Non-Final OA | — | Pending | May 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWatanabe Oyster Laboratory Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Cierra Marie Rochelle has the most, with 1 of Watanabe Oyster Laboratory Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
